Taiwan FDA registration d03c92074f13d50e6380bece878168f2
INNO-LiPA HLA-DRB1 Plus
TW: 因諾-立帕核酸探針式人類白血球抗原試劑組-DRB1位點
Taiwan·Risk Class 2·MD·FUJIREBIO EUROPE N.V.·Registered Jul 21, 2015 – Jul 21, 2025CancelledRegistration details
- Analysis ID
- d03c92074f13d50e6380bece878168f2
- License Form
- Ministry of Health Medical Device Import No. 027531
- Customs Code
- DHA05602753105
Company information
- Manufacturer
- FUJIREBIO EUROPE N.V.
- Manufacturer Country
- Belgium
- Authorized Representative
- Taiwan Fu Pharmaceutical Co., Ltd
Product details
- Product Type (Level 1)
- B Hematology and pathology devices
- Product Type (Level 2)
- B0001 Human leukocyte antigen segmentation board
- Import Information
- Imported from abroad
Dates and status
- Registration Date
- Jul 21, 2015
- Expiry Date
- Jul 21, 2025
- Cancellation Date
- Oct 28, 2022
Cancellation information
- Status
- Logged out
- Reason
- 公司歇業
About this record
Access comprehensive regulatory information for INNO-LiPA HLA-DRB1 Plus in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number d03c92074f13d50e6380bece878168f2 and manufactured by FUJIREBIO EUROPE N.V.. The authorized representative in Taiwan is Taiwan Fu Pharmaceutical Co., Ltd.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices